Language

Gastroenterology Research

Gastroenterology Research for Patients

The MultiCare Institute for Research & Innovation, in collaboration with Dr. Melawati Yuwono, provides the opportunity to participate in clinical trials to those members of our community with illnesses and diseases of the digestive tract. Our youngest patients benefit from access to personalized care provided by our research staff, a state-of-the-art endoscopy center and Dr. Yuwono's advanced training in Interventional Endoscopy.

Gastroenterology Investigators include:

Melawati Yuwono, MD

Diane Levitan, MD

Gastroenterology Studies Accepting Patients

Adult 

C-Diff Vaccine

Study Number: B5091007 - A Phase 3, placebo-controlled, randomized, observer-blinded study to evaluate the efficacy, safety, and tolerability of a Clostridium Difficile vaccine in adults 50 years of age and older.  

Study Info

Principal Investigator(s): Diane Levitan, MD

Study Coordinator: Kelly Mulligan, [email protected], 253-403-0367

Additional Information


Pediatrics

Ulcerative Colitis - M11-290

Study Number: M11-290—A multi-center, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab in pediatric subjects with moderate to severe ulcerative colitis.

Study Info

Principal Investigator(s): Melawati Yuwono, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Crohn's Disease - Cape Registry

Study Number: P11-292—A long-term non-interventional registry to assess safety and
effectiveness of Humira® (Adalimumab) in pediatric patients with moderately to
Severely Active Crohn’s Disease (CD) (CAPE).

Study Info

Principal Investigator(s): Melawati Yuwono, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Infant Formula Testing - 15.04.US.HCN

Study Number: EAGLE - A study to monitor the Use of an Amino Acid-Based Infant Formula 

Study Info

Principal Investigator(s): Melawati Yuwono, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Irritable Bowel Syndrome - Allergan 3030

Study Number: 3030-202-002 - A Phase II randomized, double-blind, palcebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of Eluxadoline in pediatric patients (age 12-17) with irritable bowel syndrome with diarrhea (IBS-D).

Study Info

Principal Investigator(s): Gad Kletter, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Constipation - Allergan 62

Study Number: LIN-MD-62 - A multicenter, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of a range of Linaclotide doses administered orally to children, ages 6 to 17 years, who fulfill modified Rome III criteria for child/ adolescent Functional Constipation (FC).

Study Info

Principal Investigator(s): Melawati Yuwono, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699

Constipation & Irritable Bowel Syndrome - Allergan 63

Study Number: LIN-MD-63 - A multicenter, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of a range of Linaclotide doses administered orally to children, ages 7 to 17 years, with irritable bowel syndrome with constipation (IBS-C) (ie, Fulfill Rome III criteria for child/ adolescent IBS and fulfill modified. Rome III criteria for child/ adolescent Functional Constipation.

Study Info

Principal Investigator(s): Melawati Yuwono, MD

Study Coordinator: Katy Garrison, [email protected], 253-403-2699